MedPAC Report Explores Ways For CMS To Use Cost-Effectiveness Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare Payment Advisory Commission’s June report to Congress suggests drug and device manufacturers that have completed cost-effectiveness analyses could share them with CMS. Advisory group also names possible federal agencies that might aid in conducting government-sponsored cost-effectiveness research for certain expensive medical products.